CENTURY THERAPEUTICS INC
Century Therapeutics, Inc (ticker IPSC) is an early-stage biotechnology company developing allogeneic cell therapies using induced pluripotent stem cells (iPSCs). The company seeks to create ‘off-the-shelf’ engineered immune cells intended to treat cancer and other diseases, aiming for scalable manufacturing and potential cost advantages versus personalised approaches. With a market capitalisation around $48.8m, Century is a small-cap, typically pre-revenue business where programmes may still be preclinical or in early clinical stages. Investors should note the high scientific, regulatory and financing risks common to cell-therapy developers: clinical trials may fail, manufacturing scale-up can be challenging, and additional capital may be required. The share price can be volatile. This summary is for general educational purposes only and is not personal financial advice; investors should carry out their own research and consider their risk tolerance and investment horizon.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Century Therapeutics' stock, expecting significant growth in its value.
Financial Health
Century Therapeutics is generating modest revenue and cash flow, with a stable book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring IPSC
Cancer Drug Safety: Could Warnings Create Opportunities?
The FDA's decision to add its strongest safety warning to a key cancer therapy from Johnson & Johnson and Legend Biotech underscores the inherent risks of powerful new treatments. This regulatory action could boost companies developing safer alternative cancer therapies, creating a new investment opportunity in the biotech sector.
Published: October 11, 2025
Explore BasketHope & Optimism Portfolio
This collection brings together pioneering companies working to solve humanity's biggest challenges through groundbreaking innovation. These carefully selected stocks represent visionaries building transformative technologies in medicine, energy, and beyond.
Published: June 18, 2025
Explore BasketCell & Gene Therapy Logistics
This carefully curated collection features companies providing the essential infrastructure that makes advanced cell and gene therapies possible. Selected by expert analysts, these stocks represent the "picks and shovels" of the biotech revolution—giving you exposure to regenerative medicine's growth without the direct risks of clinical trials.
Published: June 17, 2025
Explore BasketAge-Reversal Biotech
Invest in pioneering companies that are redefining aging as a treatable condition. These carefully selected biotechs are developing groundbreaking therapies to extend healthy lifespans and potentially reverse cellular damage, creating an entirely new frontier in medicine.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Early-stage biotech
Small market cap and early clinical programmes could offer upside if science succeeds, though outcomes are uncertain and volatility is likely.
iPSC platform potential
iPSC-derived, off-the-shelf cells aim for scalable manufacturing and broader patient reach, but technical and regulatory hurdles remain significant.
Partnerships matter
Collaborations or licences can provide funding and expertise to derisk development, yet deal terms and execution affect prospective value.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
